Literature DB >> 6433966

Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia.

R W Shaw, H M Fraser.   

Abstract

A luteinizing hormone releasing hormone agonist, D-Ser(But)6des Gly10-LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433966     DOI: 10.1111/j.1471-0528.1984.tb03708.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  7 in total

Review 1.  Management of menorrhagia.

Authors:  A L Magos
Journal:  BMJ       Date:  1990-06-16

2.  Failure to preserve fertility in patients with Hodgkin's disease.

Authors:  J H Waxman; R Ahmed; D Smith; P F Wrigley; W Gregory; S Shalet; D Crowther; L H Rees; G M Besser; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Menorrhagia. Current drug treatment concepts.

Authors:  M A van Eijkeren; G C Christiaens; P C Scholten; J J Sixma
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 4.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

Review 5.  Risk-benefit assessment of drugs used for the treatment of menstrual disorders.

Authors:  J M Higham; R W Shaw
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

Review 6.  Benefits and risks of pharmacological agents used for the treatment of menorrhagia.

Authors:  Samendra Nath Roy; Siladitya Bhattacharya
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 7.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.